ArisGlobal's LifeSphere NavaX Adopted by Sixth Global Pharma Company
ArisGlobal has announced in a press release that a sixth major pharmaceutical company has selected its LifeSphere NavaX platform to enhance case processing and pharmacovigilance operations. This adoption underscores the growing industry confidence in scalable, GenAI-enabled technologies.
The LifeSphere NavaX platform, a next-generation cognitive computing engine, is designed to improve efficiency and accuracy in case processing. The company currently processes over 150,000 adverse event cases annually using its LifeSphere MultiVigilance platform. With NavaX, the organization aims to achieve up to 65% efficiency gains and 90% data accuracy in intake. The implementation is expected to go live in the fall of 2025.
This strategic move reflects a commitment to deploying cutting-edge technologies for significant workflow efficiencies and cost savings. Future plans include expanding NavaX's use to signal detection, medical review augmentation, and global reporting, further cementing its role as a driver of innovation in the pharmaceutical industry.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more